arginyl-glycyl-aspartic acid has been researched along with Endometrial Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghorbani, M; Hajipour, H; Mirzamohammadi, Z; Nouri, M; Sambrani, R | 1 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Endometrial Neoplasms
| Article | Year |
|---|---|
Sildenafil citrate-loaded targeted nanostructured lipid carrier enhances receptivity potential of endometrial cells via LIF and VEGF upregulation.
Topics: Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Endometrial Neoplasms; Endometrium; Female; Humans; Leukemia Inhibitory Factor; Liposomes; Nanoparticles; Oligopeptides; Particle Size; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Up-Regulation; Vascular Endothelial Growth Factor A | 2021 |